Connect with us

Press Release

RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring’s Rebyota® and Clenpiq®

Published

2 months ago

on

Raleigh, United States, September 1st, 2026, FinanceWire

Together with the previously announced Talicia strategic divestiture, the acquisition from Ferring of commercialization rights to two larger, proprietary, established gastrointestinal (GI) FDA-approved drugs that together generated approximately $37.5 million in 2025 net sales, completes a major strategic repositioning of RedHill’s commercial GI business

The divestiture of Talicia and the acquisition of the new GI products from Ferring create a catalyst for commercial growth through a materially larger GI business under RedHill’s control, with a significantly stronger liquidity position and provides additional growth and expansion opportunities

Under the terms of the agreement, RedHill obtained the exclusive commercialization rights for an upfront payment to Ferring of $12 million plus potential future milestones and tiered royalties.

The $12 million upfront payment is fully funded through the previously announced $18 million Talicia divestment, with RedHill securing exclusive global and U.S. commercialization rights to Ferring’s Rebyota and Clenpiq, respectively – two synergistic, revenue-generating, FDA-approved GI drugs

Rebyota is a proprietary, first and only single-dose FDA-approved Fecal Microbiota Transplant (FMT for prevention of recurrent C. diff infection (rCDI). FDA-approved in 2022 and Health Canada-approved in 2025, Rebyota, was granted a Breakthrough Therapy and received Orphan Drug designations and generated approximately $16.9 million in 2025 U.S. net sales

Proprietary Clenpiq, a ready-to-use (no mixing required) low-volume bowel preparation on the U.S. market, generated $20.6 million in U.S. 2025 net sales with minimal promotion 

RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced the transformational acquisition of exclusive global and U.S. commercialization rights to Rebyota and Clenpiq, from Ferring Pharmaceuticals (“Ferring”), as part of Ferring’s ongoing strategic refocusing.

Dror Ben-Asher, RedHill’s Chief Executive Officer, said: “We have executed a clear strategic sequence. We have monetized Talicia for $18 million cash upfront, plus $35 million in potential upside, used $12 million to secure commercialization rights to two established, proprietary, FDA-approved gastrointestinal drugs, that collectively generated approximately $37.5 million in U.S. net sales in 2025, and emerged with a materially larger, fully controlled commercial business and a stronger liquidity position. Rebyota and Clenpiq are expected to generate a positive cash contribution to RedHill. This, combined with RedHill’s experienced and lean commercial team and proven development capabilities, creates a scalable foundation for further growth, including additional acquisition of complementary revenue-generating products.” Mr. Ben-Asher added: “We thank Ferring for a smooth process to date and look forward to a successful collaboration.”

Under the terms of the agreement, RedHill obtained an exclusive global commercialization license of Rebyota and an exclusive U.S. commercialization license of Clenpiq, for an upfront payment to Ferring of $12 million, plus tiered royalties on net sales and potential milestones. Ferring retains its Rebyota manufacturing facilities, and Ferring will continue to supply Rebyota through the term of the agreement.

“Rebyota is a first-in-class microbiota-based therapy for prevention of recurrent Clostridioides difficile (C. diff) infection (rCDI) in individuals 18 years of age and older following antibiotic treatment for rCDI. FDA-approved in 2022, it generated approximately $16.9 million in U.S. net sales in 2025 through its clinical profile, broad coverage and an established customer base of approximately 600 active accounts,” said Rick Scruggs, RedHill’s Chief Commercial Officer. “Clenpiq, a ready-to-drink low-volume bowel preparation on the U.S. market, delivered $20.6 million in net sales in 2025, with minimal promotion. Together the two assets give RedHill a significantly stronger commercial growth engine in both the U.S. and other new territories.”

C. diff (CDI) infection is a distressing and life-threatening condition – in developed countries it is the most common cause of healthcare-associated (HA) diarrhea. An estimated 3.6 million cases of CDI occur globally each year, including approximately half a million cases in the U.S. 30,000 Americans die every year due to CDI, with a global mortality rate of 1-in-10, rising to almost 1-in-3 in high-risk settings1. In the U.S., up to approximately 165,000 CDI cases result in one or more recurrences, indicating the need for use of prevention strategies.

Rebyota’s one-time administration, which requires no fasting, bowel prep or extended treatment timeframe, has demonstrated more than a 70% success rate at preventing rCDI. An aging population and accompanying increasing hospital-acquired vulnerabilities will likely increase this need. A streamlined ordering and reimbursement process is already in place for physicians, and broad and improving U.S. payer coverage means that 93% of lives have coverage including 43% with coverage after 1st recurrence.

Rebyota, which was granted, Breakthrough Therapy and Orphan Drug designations – with exclusivities and other patent protections that could run to 2036, provides multiple growth opportunities, including recent approval in Canada. The existing approvals also provide the potential for additional approvals in other territories.

Colonoscopy is the cornerstone of GI practice, with more than 15 million colonoscopies performed in the U.S. annually. This number is rising, with follow-up needed after noninvasive screening tests that yield a positive result, an aging population, and guidelines that recommend testing at age 45 instead of age 50, contributing to an increased need for colonoscopy. Bowel preparation is not a pleasant process and is often poorly performed.

Clenpiq is a ready-to-drink low-volume bowel prep. Clenpiq is readily available to patients and has broad commercial and government payer coverage: More than 108 million lives (63%) with unrestricted (no prior approval) have commercial coverage, including 57 million (33%) with preferred position. 23m lives (41%) of Medicare Part D lives have unrestricted access to Clenpiq, including 12m (21%) lives with preferred position5.

RedHill was advised by Morningstar Law Group and Greenberg Traurig LLP on this transaction.

About RedHill Biopharma  

RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company primarily focused on U.S. development and commercialization of drugs for gastrointestinal diseases, infectious diseases and oncology. RedHill promotes the FDA-approved gastrointestinal therapies Rebyota, for the prevention of recurrent C. diff infection (rCDI), and the bowel preparation treatment, Clenpiq. RedHill’s key clinical late-stage development programs include: (i) opaganib (ABC294640), a first-in-class, orally administered sphingosine kinase-2 (SPHK2) selective inhibitor with anti-inflammatory, antiviral, metabolic and anticancer activity, targeting multiple indications with a track record of U.S. government and academic collaborations intended for medical countermeasure development including for EVD, radiation exposure indications such as GI-Acute Radiation Syndrome (GI-ARS), a Phase 2/3 program for hospitalized COVID-19, and an ongoing Phase 2 study in prostate cancer in combination with darolutamide; (ii) RHB-102 (Bekinda), with a planned Phase 2 proof-of-concept study for GLP-1/GIP receptor agonist-associated GI intolerance, positive results from a U.S. Phase 3 study for acute gastroenteritis and gastritis, positive results from a U.S. Phase 2 study for IBS-D and potential UK submission for chemotherapy and radiotherapy induced nausea and vomiting. RHB-102 is partnered with Hyloris Pharmaceuticals (EBR: HYL) for worldwide development and commercialization outside North America; (iii) RHB-204, a next-generation optimized formulation of RHB-104, with a planned Phase 2 study for Crohn’s disease (based on RHB-104’s positive Phase 3 Crohn’s disease study results); and (iv) RHB-107 (upamostat), an oral broad-acting, host-directed, serine protease inhibitor with potential for pandemic preparedness, including COVID-19 and also targeting multiple cancer and inflammatory gastrointestinal diseases.

More information about the Company is available at www.redhillbio.com / X.com/RedHillBio.

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and may discuss investment opportunities, stock analysis, financial performance, investor relations, and market trends. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words, and include, among others, statements regarding the divestment of Talicia and the potential use of the proceeds of such sale; the expected benefits of the acquisition of commercialization rights to Rebyota and Clenpiq, the anticipated commercial growth and cash contribution from these products, expectations regarding market share growth, anticipated payer coverage, the Company’s strategic repositioning and path to operational profitability, potential use of milestone and royalty payments, and the Company’s ability to successfully commercialize Rebyota and Clenpiq. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified, and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. 

[i] Akorful RAA, Odoom A, Awere-Duodu A, Donkor ES. The Global Burden of Clostridioides difficile Infections, 2016-2024: A Systematic Review and Meta-Analysis. Infect Dis Rep. 2025 Apr 14;17(2):31. doi: 10.3390/idr17020031. PMID: 40277958; PMCID: PMC12026862.

[ii] Lessa FC, Mu Y, Bamberg WM, Beldavs ZG, Dumyati GK, Dunn JR, Farley MM, Holzbauer SM, Meek JI, Phipps EC, Wilson LE, Winston LG, Cohen JA, Limbago BM, Fridkin SK, Gerding DN, McDonald LC. Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015 Feb 26;372(9):825-34. doi: 10.1056/NEJMoa1408913. PMID: 25714160; PMCID: PMC10966662.

[iii] Feuerstadt P, Theriault N, Tillotson G. The burden of CDI in the United States: a multifactorial challenge. BMC Infect Dis. 2023 Mar 7;23(1):132. doi: 10.1186/s12879-023-08096-0. PMID: 36882700; PMCID: PMC9990004.

[iv] Khanna S, Assi M, Lee C, et al. Efficacy and safety of RBX2660 in PUNCH CD3, a phase III, randomized, double-blind, placebo-controlled trial with a Bayesian primary analysis for the prevention of recurrent Clostridioides difficile infection. Drugs. 2022;82(15):1527-1538. doi:10.1007/s40265-022-01797-x.

[v] Data on file. Ferring Pharmaceuticals

[vi] MarketScan Commercial Claims and Encounters and Medicare Supplemental database

Contact

Chief Corporate and BD Officer
Adi Frish
RedHill Biopharma
adi@redhillbio.com

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Related Topics:
Continue Reading

Press Release

Karviva and Founder Dr. Angela Zeng Featured in 2026 USA TODAY Food as Medicine Edition.

Published

1 day ago

on

October 17, 2026

By

Full-page feature highlights founder Dr. Angela Zeng’s approach to combining traditional wellness principles with modern nutrition

Saint Louis, MO, United States, 17th Oct 2026 – Karviva, the functional beverage company founded by Dr. Angela Zeng, is featured in the 2026 USA TODAY Food as Medicine special edition, with a full-page feature appearing on page 23 in both the digital and print editions. According to information provided by USA TODAY, approximately 250,000 printed copies of the special edition are expected to be in circulation. The feature highlights Dr. Zeng’s background as a medical scientist, her family’s generations-long connection to Traditional Chinese Medicine, and the thinking behind Karviva’s whole-plant beverage portfolio.

The feature, titled “Why a Medical Scientist Built a Gentler Cleanse,” explores Dr. Zeng’s personal and professional path and the ideas that led her to create Karviva. It highlights the company’s use of whole-plant ingredients, including fruits, vegetables, sprouts, herbs, and botanicals, as well as its approach to developing juice products without added sugar or harsh laxatives.

Dr. Zeng founded Karviva after combining her scientific training with the traditional wellness practices she grew up around. Her background includes a Ph.D. in Pathology and training in evidence-based nutrition, while her family history introduced her to Traditional Chinese Medicine from an early age.

“A cleanse should not feel like a punishment,” said Dr. Angela Zeng. “It should give you space to hydrate, simplify your meals, and pay attention to what your body needs.”

The USA TODAY appearance adds to a series of recent milestones for Dr. Zeng and Karviva. Dr. Zeng’s debut book, The Balance Cure: The TCM Way to Lasting Weight Loss, has reached the No. 1 bestseller position in Amazon’s Holistic Medicine category. The book explores Traditional Chinese Medicine alongside modern nutrition and introduces readers to five TCM body patterns, self-assessments, seasonal observations, recipes, and lifestyle reflections.

Karviva has also recently received recognition from Good Housekeeping, with the company’s Profit Cacao Whole Plant Protein & Prebiotic Smoothie selected as a winner of the 2026 Snack Awards. The recognition followed evaluations by the Good Housekeeping Institute Nutrition Lab and consumer testing as part of the award program.

The new USA TODAY feature offers readers a closer look at the founder behind Karviva and the ideas that continue to shape the company’s approach to functional beverages.

About Dr. Angela Zeng

Dr. Angela Zeng, Ph.D., MBA, is a food scientist, Traditional Chinese Medicine scholar, and founder and CEO of Karviva. Born into generations of Chinese herbal practitioners and trained in pathology, biochemistry, and evidence-based nutrition, she combines traditional wellness principles with modern nutritional science through her work as an entrepreneur, author, and speaker. She is the author of The Balance Cure: The TCM Way to Lasting Weight Loss.

About Karviva

Karviva is a St. Louis-based functional beverage company founded by Dr. Angela Zeng. Inspired by Traditional Chinese Medicine and modern nutritional science, the company develops plant-based beverages using whole-food ingredients, botanicals, and prebiotic fiber. Its portfolio includes juices, protein smoothies, hydration beverages, and other functional drinks.

Media Contact

Organization: Karviva

Contact Person: Dr. Angela Zeng

Website: https://karviva.com/

Email:
angela@karviva.com

City: Saint Louis

State: MO

Country: United States

Release id: 49986

View source version on King Newswire:
Karviva and Founder Dr. Angela Zeng Featured in 2026 USA TODAY Food as Medicine Edition.

file

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

U-topia Launches Public Beta as Global Builders Gather for U-Hackathon

Published

1 day ago

on

October 17, 2026

By

Financial technology company opens its app in more than 50 countries during FLOW Summit as 500-plus builders develop AI and Web3 products

BANGKOK, Oct. 17, 2026, ZEX PR WIRE  — U-topia, a financial technology company building a self-custody app for everyday money movement, has opened its public beta in more than 50 countries. The company announced the launch at FLOW Summit 2026, held Oct. 15-16 at Avani Sukhumvit Bangkok, five years after U-topia was founded.

More than 700 people attended the two-day launch, including technology entrepreneurs, developers and community members from several countries. The program combined U-topia product demonstrations and company updates with U-Hackathon, a global build program focused on practical AI and Web3 products.

“Five years ago, I set a simple standard: if my mother could not use the product without calling me for help, it was not ready,” said Emmanuel Quezada, founder and CEO of U-topia. “Opening the beta with people from around the world, while hundreds of builders were creating new tools beside us, brought that idea to life. Our goal is to make moving money as simple as sending a message while keeping people in control.”

A public beta designed around everyday use

U-topia is designed to let eligible users hold, send, spend, convert and withdraw digital and everyday currencies through one mobile app. Users can send funds to another U-topia user through a U-Tag, a simple @name that replaces a long wallet address. The company says funds remain under the user’s control rather than being held by U-topia.

The public beta follows private alpha and closed beta testing with community members and ambassadors. Feature availability varies by country. Account opening, card issuance and transactions remain subject to age requirements, identity verification, partner rules and local law. U-topia is not a bank or card issuer; card and local currency services are provided through licensed partners where available.

U-Hackathon brings global builders to Bangkok

FLOW Summit also hosted U-Hackathon on Oct. 15-16. Organizers said the event attracted more than 500 hackers and builders from around the world. Teams worked through a 24-hour build period with product, engineering and design mentors before presenting working prototypes in two tracks: artificial intelligence and Web3. The program extended the app launch into a working forum for new products, technical collaboration and international builder participation.

The competition recognized three teams in each track. Organizers valued the combined awards at more than 2.5 million Thai baht, including the advertised THB 1 million core prize pool, partner bounties and technology credits. UBotPay, an AI-powered payment agent built for Web3, won first place in the Web3 track. U-Reach, an AI-powered marketing, sales and customer relationship management platform, took first place in the AI track.

U-Hackathon was sponsored by ElevenLabs, Tokenomist AI and DTC Group, in association with Avalanche, Team1 Thailand, Yellow.com, ContributionDAO, CUBS Chula and Hooray. Judges selected projects on merit, and members of the U-Center DAO community voted live for the grand prize.

The summit also included a preview of U.bot, a related AI venture from members of U-topia’s founding team. U.bot is being developed as a user-controlled orchestration layer that can select among AI models and coordinate specialized agents. Its long-term roadmap aims to create a more capable personal AI experience with characteristics the team associates with superintelligence; those advanced capabilities are planned and are not currently available.

About U-topia

Founded on Oct. 16, 2021, U-topia is a financial technology company building a self-custody mobile app intended to help people hold, send, spend, convert and withdraw digital and everyday currencies while retaining control of their funds. U-topia is not a bank and does not issue cards. Availability and features vary by country and are subject to partner requirements and local law. Learn more at www.u-topia.com.

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

From Karmayogi to the World Stage: Dr. Hemant Garg Wins “Excellence in AI for Public Policy”, Charts India’s Path to the AI Big League

Published

1 day ago

on

October 17, 2026

By

Civil servant, researcher and AI pioneer tells the 3rd World AI Summit, Bengaluru, that people-first, sovereign AI can make India a global AI leader

Bengaluru, India, 16th October 2026, ZEX PR WIRE  — Dr. Hemant Garg, Deputy Director (Legal), Employees’ State Insurance Corporation (ESIC), Ministry of Labour and Employment, Government of India, received the “Excellence in AI for Public Policy” award at the 3rd World AI Summit in Bengaluru on 14–15 October 2026, placing an Indian public-policy voice at the centre of the global debate on how AI should serve people.

Dr. Garg described all of his work, from AI agents for government to AI-led labour law outreach, as an effort to help realise Hon’ble Prime Minister Shri Narendra Modi’s vision of Viksit Bharat@2047, under the leadership of Hon’ble Union Labour and Employment Minister Dr. Mansukh Mandaviya, whose Shramev Jayate reforms, Labour Codes and Ease of Doing Business drive set the direction. The goal, he said, is an Atmanirbhar Bharat in AI, built on a Bharat AI Stack: Indian large language models such as Sarvam, the Bhashini platform serving citizens in their own languages, and home-grown agents and talent under the IndiaAI Mission, taking India into the global AI league.

Held with Digital India, the National e-Governance Division (NeGD) and the Karnataka Digital Economy Mission (KDEM) as partners in Bengaluru, India’s startup, IT and now AI capital, often called India’s Silicon Valley, the Summit was themed “AI for All: Accelerating India’s Journey Towards Inclusive, Responsible and Future-Ready AI”.

The award honours his creation in 2023 of “IFSCA Karmayogi”, the first AI agent at the International Financial Services Centres Authority (IFSCA), GIFT City, and his research on AI in anti-money laundering, the Labour Codes and algorithmic management of gig workers.

On the panel “AI for All – India’s Journey to a Sovereign, Inclusive AI Future”, with Shri Aman Mittal, IAS, Dr. BVRC Purushottam, IAS and Prof. (Dr.) T. G. Sitharam, former Chairman, AICTE, moderated by Dr. Ravi Gupta, Dr. Garg said inclusive AI must include the worker, and that India can blend Europe’s rights-based approach, US-style audits and Singapore’s skilling model through its Labour Codes, the DPDP Act and e-Shram.

His keynote, “AI, Employment & Skills: Building a Future-Ready Workforce for India”, presented as “From Files to Foresight”, began with a worker disabled in an accident, or a family that has lost its breadwinner, whose care and pensions depend on ESIC, EPFO, the Ministry of Labour and Employment and the National Health Authority. “The true test of AI in government is how quickly that family receives its benefits, and whether it is treated with dignity on the way,” he said.

He traced three waves of governance: e-Governance, which put paper online; Digital Governance, built on India’s digital public infrastructure; and now AI-enabled Intelligent Governance, where benefits reach eligible citizens without their having to apply.

Dr. Garg propounded that AI will change tasks first, then jobs, then institutions and the workforce, and called for institutions for AI governance, impact assessment and exposure mapping to curb job attrition, support reskilling and compensate workers in transition. e-Shram, ESIC and EPFO, now reaching gig and platform workers, can extend social security to those left out, while indigenous models such as Sarvam and Bhashini can grow home-grown AI talent under the IndiaAI Mission.

Government AI, he said, must be lawful, explainable and accountable; “a pattern is not proof”; and India must guard against a new colonisation “not by ships, but by servers”. He proposed “Five Ts”: Trust, Transparency, Talent, Thin and safe data, and Tested-then-scaled.

An LLB, LLM and Ph.D., and an IIT Delhi CTO Programme alumnus with nearly two decades in public service, including Punjab’s Department of Cooperation, Dr. Garg has researched digital governance in governments and cooperatives extensively; his work is published internationally, taught in universities and presented at Oxford, Harvard and Cambridge.

“Not artificial intelligence replacing governance, but intelligent governance that remains deeply human,” he concluded.

Connect with Dr. Hemant Garg on LinkedIn: https://in.linkedin.com/in/dr-hemant-garg-2b26699

About Author

Cloud PR Wire

See author's posts

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

LATEST POST

Like Us
Follow Us
Subscribe Us
Follow Us